S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Hepion Pharmaceuticals Stock Forecast, Price & News

-0.02 (-1.06 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $1.86
50-Day Range
MA: $2.30
52-Week Range
Now: $1.86
Volume6.12 million shs
Average Volume6.11 million shs
Market Capitalization$141.78 million
P/E RatioN/A
Dividend YieldN/A
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of pleiotropic drug therapy for the treatment of chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that has completed the Phase I clinical trials for multiple biochemical pathways involved in the progression of liver diseases; and Tenofovir exalidex, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Hepion Pharmaceuticals logo


Hepion Pharmaceuticals Announces Pricing of Public Offering
February 16, 2021 |  finance.yahoo.com
Hepion Pharmaceuticals Inc
January 16, 2021 |  cnbc.com
Hepion up Slightly on Release of CRV Results
December 30, 2020 |  baystreet.ca
5 Stocks To Watch For December 30, 2020
December 30, 2020 |  msn.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HEPA
Phone732 902 4000
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$4.19 per share


Net Income$-6,720,000.00


Market Cap$141.78 million
Next Earnings Date5/13/2021 (Estimated)


Overall MarketRank

1.82 out of 5 stars

Medical Sector

150th out of 1,972 stocks

Pharmaceutical Preparations Industry

65th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
-0.02 (-1.06 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HEPA News and Ratings via Email

Sign-up to receive the latest news and ratings for HEPA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Hepion Pharmaceuticals (NASDAQ:HEPA) Frequently Asked Questions

Is Hepion Pharmaceuticals a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Hepion Pharmaceuticals stock.
View analyst ratings for Hepion Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Hepion Pharmaceuticals?

Wall Street analysts have given Hepion Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Hepion Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Hepion Pharmaceuticals?

Hepion Pharmaceuticals saw a increase in short interest in the month of February. As of February 12th, there was short interest totaling 696,500 shares, an increase of 159.7% from the January 28th total of 268,200 shares. Based on an average daily trading volume, of 4,900,000 shares, the days-to-cover ratio is presently 0.1 days.
View Hepion Pharmaceuticals' Short Interest

When is Hepion Pharmaceuticals' next earnings date?

Hepion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Hepion Pharmaceuticals

How were Hepion Pharmaceuticals' earnings last quarter?

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced its earnings results on Sunday, November, 15th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.18.
View Hepion Pharmaceuticals' earnings history

How has Hepion Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Hepion Pharmaceuticals' stock was trading at $2.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HEPA shares have decreased by 11.0% and is now trading at $1.86.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HEPA?

1 Wall Street analysts have issued 1 year target prices for Hepion Pharmaceuticals' shares. Their forecasts range from $80.00 to $80.00. On average, they anticipate Hepion Pharmaceuticals' share price to reach $80.00 in the next year. This suggests a possible upside of 4,201.1% from the stock's current price.
View analysts' price targets for Hepion Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Hepion Pharmaceuticals' key executives?

Hepion Pharmaceuticals' management team includes the following people:
  • Dr. Robert T. Foster B.Sc., BSc (Pharm), Pharm.D., Ph.D., Pres, CEO & Director (Age 63, Pay $600k)
  • Mr. John T. Cavan, Chief Financial Officer (Age 63, Pay $364.05k)
  • Dr. Daren Ure Ph.D., Chief Scientific Officer
  • Sharen Pyatetskaya, Director of Investor Relations
  • Dr. Daniel Trepanier Ph.D., Sr. VP of Drug Devel.
  • Dr. Patrick Mayo Ph.D., Sr. VP of Clinical Pharmacology
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant (Age 73)
  • Dr. Stephen A. Harrison, Member of Scientific Advisory Board & Consultant Medical Director

Who are some of Hepion Pharmaceuticals' key competitors?

What other stocks do shareholders of Hepion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), (AZN), Axsome Therapeutics (AXSM), Archrock (AROC), (APHA), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV).

What is Hepion Pharmaceuticals' stock symbol?

Hepion Pharmaceuticals trades on the NASDAQ under the ticker symbol "HEPA."

Who are Hepion Pharmaceuticals' major shareholders?

Hepion Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.23%), Renaissance Technologies LLC (3.65%), Worth Venture Partners LLC (2.59%), Perkins Capital Management Inc. (1.66%), Squarepoint Ops LLC (1.24%) and GSA Capital Partners LLP (0.99%). Company insiders that own Hepion Pharmaceuticals stock include Gary S Jacob, John T Cavan, Peter Wijngaard and Robert T Foster.
View institutional ownership trends for Hepion Pharmaceuticals

Which institutional investors are buying Hepion Pharmaceuticals stock?

HEPA stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Worth Venture Partners LLC, Perkins Capital Management Inc., Squarepoint Ops LLC, GSA Capital Partners LLP, Northern Trust Corp, and Bank of New York Mellon Corp. Company insiders that have bought Hepion Pharmaceuticals stock in the last two years include Gary S Jacob, John T Cavan, Peter Wijngaard, and Robert T Foster.
View insider buying and selling activity for Hepion Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Hepion Pharmaceuticals?

Shares of HEPA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hepion Pharmaceuticals' stock price today?

One share of HEPA stock can currently be purchased for approximately $1.86.

How much money does Hepion Pharmaceuticals make?

Hepion Pharmaceuticals has a market capitalization of $141.78 million. The company earns $-6,720,000.00 in net income (profit) each year or ($5.95) on an earnings per share basis.

How many employees does Hepion Pharmaceuticals have?

Hepion Pharmaceuticals employs 12 workers across the globe.

What is Hepion Pharmaceuticals' official website?

The official website for Hepion Pharmaceuticals is www.hepionpharma.com.

Where are Hepion Pharmaceuticals' headquarters?

Hepion Pharmaceuticals is headquartered at 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837.

How can I contact Hepion Pharmaceuticals?

Hepion Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The company can be reached via phone at 732 902 4000 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.